176 related articles for article (PubMed ID: 15026360)
1. Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells.
Conejo-Garcia JR; Benencia F; Courreges MC; Gimotty PA; Khang E; Buckanovich RJ; Frauwirth KA; Zhang L; Katsaros D; Thompson CB; Levine B; Coukos G
Cancer Res; 2004 Mar; 64(6):2175-82. PubMed ID: 15026360
[TBL] [Abstract][Full Text] [Related]
2. Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells.
Conejo-Garcia JR; Benencia F; Courreges MC; Khang E; Zhang L; Mohamed-Hadley A; Vinocur JM; Buckanovich RJ; Thompson CB; Levine B; Coukos G
Cancer Biol Ther; 2003; 2(4):446-51. PubMed ID: 14508119
[TBL] [Abstract][Full Text] [Related]
3. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells.
Ehrlich LI; Ogasawara K; Hamerman JA; Takaki R; Zingoni A; Allison JP; Lanier LL
J Immunol; 2005 Feb; 174(4):1922-31. PubMed ID: 15699119
[TBL] [Abstract][Full Text] [Related]
4. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
[TBL] [Abstract][Full Text] [Related]
5. NKG2D receptor activation of NF-κB enhances inflammatory cytokine production in murine effector CD8(+) T cells.
Whitman E; Barber A
Mol Immunol; 2015 Feb; 63(2):268-78. PubMed ID: 25089028
[TBL] [Abstract][Full Text] [Related]
6. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity.
Groh V; Smythe K; Dai Z; Spies T
Nat Immunol; 2006 Jul; 7(7):755-62. PubMed ID: 16732291
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
8. The role of the NKG2D immunoreceptor in immune cell activation and natural killing.
Jamieson AM; Diefenbach A; McMahon CW; Xiong N; Carlyle JR; Raulet DH
Immunity; 2002 Jul; 17(1):19-29. PubMed ID: 12150888
[TBL] [Abstract][Full Text] [Related]
9. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma.
Wu JY; Ernstoff MS; Hill JM; Cole B; Meehan KR
Cytotherapy; 2006; 8(2):141-8. PubMed ID: 16698687
[TBL] [Abstract][Full Text] [Related]
11. Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation.
Markiewicz MA; Carayannopoulos LN; Naidenko OV; Matsui K; Burack WR; Wise EL; Fremont DH; Allen PM; Yokoyama WM; Colonna M; Shaw AS
J Immunol; 2005 Sep; 175(5):2825-33. PubMed ID: 16116168
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.
Sheu BC; Chiou SH; Lin HH; Chow SN; Huang SC; Ho HN; Hsu SM
Cancer Res; 2005 Apr; 65(7):2921-9. PubMed ID: 15805295
[TBL] [Abstract][Full Text] [Related]
13. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction.
André MC; Sigurdardottir D; Kuttruff S; Pömmerl B; Handgretinger R; Rammensee HG; Steinle A
Int J Cancer; 2012 Oct; 131(7):1601-10. PubMed ID: 21607945
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic measles virus enhances antitumour responses of adoptive CD8
Chen A; Zhang Y; Meng G; Jiang D; Zhang H; Zheng M; Xia M; Jiang A; Wu J; Beltinger C; Wei J
Sci Rep; 2017 Jul; 7(1):5170. PubMed ID: 28701757
[TBL] [Abstract][Full Text] [Related]
15. Human tumor-derived exosomes down-modulate NKG2D expression.
Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
[TBL] [Abstract][Full Text] [Related]
16. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
Diefenbach A; Jensen ER; Jamieson AM; Raulet DH
Nature; 2001 Sep; 413(6852):165-71. PubMed ID: 11557981
[TBL] [Abstract][Full Text] [Related]
17. Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer.
Katou F; Ohtani H; Watanabe Y; Nakayama T; Yoshie O; Hashimoto K
Cancer Res; 2007 Dec; 67(23):11195-201. PubMed ID: 18056444
[TBL] [Abstract][Full Text] [Related]
18. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.
Webb JR; Wick DA; Nielsen JS; Tran E; Milne K; McMurtrie E; Nelson BH
Gynecol Oncol; 2010 Sep; 118(3):228-36. PubMed ID: 20541243
[TBL] [Abstract][Full Text] [Related]
19. Functional dichotomy between NKG2D and CD28-mediated co-stimulation in human CD8+ T cells.
Rajasekaran K; Xiong V; Fong L; Gorski J; Malarkannan S
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844584
[TBL] [Abstract][Full Text] [Related]
20. The activating immunoreceptor NKG2D and its ligands are involved in allograft transplant rejection.
Kim J; Chang CK; Hayden T; Liu FC; Benjamin J; Hamerman JA; Lanier LL; Kang SM
J Immunol; 2007 Nov; 179(10):6416-20. PubMed ID: 17982029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
